valproic acid has been researched along with Cancer of Head in 9 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Excerpt | Relevance | Reference |
---|---|---|
"Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage." | 6.82 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. ( Aversa, C; Botti, G; Bruzzese, F; Budillon, A; Calogero, E; Caponigro, F; Cavalcanti, E; D'Aniello, R; Daponte, A; De Cecio, R; De Feo, G; Di Gennaro, E; Di Marzo, M; Ionna, F; Longo, F; Losito, NS; Maglione, MG; Maiolino, P; Montano, M; Muto, P; Pavone, E; Perri, F; Petrillo, A; Pontone, M; Sandomenico, F; Scala, S; Trotta, A; Zotti, AI, 2016) |
"Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage." | 2.82 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. ( Aversa, C; Botti, G; Bruzzese, F; Budillon, A; Calogero, E; Caponigro, F; Cavalcanti, E; D'Aniello, R; Daponte, A; De Cecio, R; De Feo, G; Di Gennaro, E; Di Marzo, M; Ionna, F; Longo, F; Losito, NS; Maglione, MG; Maiolino, P; Montano, M; Muto, P; Pavone, E; Perri, F; Petrillo, A; Pontone, M; Sandomenico, F; Scala, S; Trotta, A; Zotti, AI, 2016) |
"Valproic acid is an antiepileptic drug with more than 50 years of clinical use." | 2.61 | El ácido valproico como agente sensibilizador al tratamiento anticáncer. ( Correa-Basurto, J; Luna-Palencia, GR; Vásquez-Moctezuma, I, 2019) |
"Growth inhibition profiles of HNSCC cell lines varied in response to VPA." | 1.38 | Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. ( Cheong, SC; Gan, CP; Hamid, S; Hor, SY; Ismail, SM; Saunders, N; Teo, SH; Wan Mustafa, WM; Zain, RB, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 7 (77.78) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
Authors | Studies |
---|---|
Luna-Palencia, GR | 1 |
Correa-Basurto, J | 1 |
Vásquez-Moctezuma, I | 1 |
Gama, RR | 1 |
Arantes, LMRB | 1 |
Sorroche, BP | 1 |
De Marchi, P | 1 |
Melendez, ME | 1 |
Carvalho, RS | 1 |
de Lima, MA | 1 |
Vettore, AL | 1 |
Carvalho, AL | 1 |
Lee, BS | 1 |
Kim, YS | 2 |
Kim, HJ | 1 |
Kim, DH | 1 |
Won, HR | 1 |
Kim, CH | 1 |
Kang, H | 1 |
Gillespie, TW | 1 |
Goodman, M | 1 |
Brodie, SA | 1 |
Brandes, M | 1 |
Ribeiro, M | 1 |
Ramalingam, SS | 1 |
Shin, DM | 1 |
Khuri, FR | 1 |
Brandes, JC | 1 |
Lee, SH | 1 |
Nam, HJ | 1 |
Kang, HJ | 1 |
Samuels, TL | 1 |
Johnston, N | 1 |
Lim, YC | 1 |
Caponigro, F | 1 |
Di Gennaro, E | 1 |
Ionna, F | 1 |
Longo, F | 1 |
Aversa, C | 1 |
Pavone, E | 1 |
Maglione, MG | 1 |
Di Marzo, M | 1 |
Muto, P | 1 |
Cavalcanti, E | 1 |
Petrillo, A | 1 |
Sandomenico, F | 1 |
Maiolino, P | 1 |
D'Aniello, R | 1 |
Botti, G | 1 |
De Cecio, R | 1 |
Losito, NS | 1 |
Scala, S | 1 |
Trotta, A | 1 |
Zotti, AI | 1 |
Bruzzese, F | 1 |
Daponte, A | 1 |
Calogero, E | 1 |
Montano, M | 1 |
Pontone, M | 1 |
De Feo, G | 1 |
Perri, F | 1 |
Budillon, A | 1 |
Kothari, V | 1 |
Joshi, G | 1 |
Nama, S | 1 |
Somasundaram, K | 1 |
Mulherkar, R | 1 |
Gan, CP | 1 |
Hamid, S | 1 |
Hor, SY | 1 |
Zain, RB | 1 |
Ismail, SM | 1 |
Wan Mustafa, WM | 1 |
Teo, SH | 1 |
Saunders, N | 1 |
Cheong, SC | 1 |
Erlich, RB | 1 |
Rickwood, D | 1 |
Coman, WB | 1 |
Saunders, NA | 1 |
Guminski, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736] | Early Phase 1 | 42 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck[NCT02624128] | Phase 2 | 39 participants (Anticipated) | Interventional | 2015-02-23 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for valproic acid and Cancer of Head
Article | Year |
---|---|
El ácido valproico como agente sensibilizador al tratamiento anticáncer.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Ne | 2019 |
2 trials available for valproic acid and Cancer of Head
Article | Year |
---|---|
Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid.
Topics: Acetylation; DNA Methylation; Double-Blind Method; Female; Head and Neck Neoplasms; Histones; Humans | 2021 |
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetu | 2016 |
6 other studies available for valproic acid and Cancer of Head
Article | Year |
---|---|
HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells.
Topics: Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Syner | 2018 |
Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cohort Studies; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Histon | 2014 |
Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2015 |
HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model.
Topics: Adenoviruses, Human; Animals; Bystander Effect; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined | 2010 |
Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence.
Topics: Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Differen | 2012 |
Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.
Topics: Acetylation; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Prolifer | 2009 |